Holen Sie sich die Stockscreener-App
1.29
2.27%
-0.03
Handel nachbörslich:
1.28
-0.01
-0.78%
Schlusskurs vom Vortag:
$1.32
Offen:
$1.27
24-Stunden-Volumen:
724.05K
Relative Volume:
0.32
Marktkapitalisierung:
$29.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.58M
KGV:
-0.2854
EPS:
-4.52
Netto-Cashflow:
$-42.82M
1W Leistung:
-11.03%
1M Leistung:
+28.36%
6M Leistung:
-16.77%
1J Leistung:
+72.00%
1-Tages-Spanne:
$1.24
$1.32
1-Wochen-Bereich:
$1.16
$1.44
52-Wochen-Spanne:
$0.705
$2.50
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Firmenname
Iterum Therapeutics Plc
Sektor
Branche
Telefon
(872) 225-6077
Adresse
FITZWILLIAM COURT, 1ST FLOOR, DUBLIN 2
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Herabstufung | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Iterum Therapeutics Plc Aktie (ITRM) Neueste Nachrichten
Iterum Therapeutics defers $20 million FDA milestone payment By Investing.com - Investing.com Australia
Iterum Therapeutics defers $20 million FDA milestone payment - Investing.com India
Iterum Therapeutics : Financial Obligation Form 8 K - Marketscreener.com
ITRMIterum Therapeutics plc Ordinary Share Latest Stock News & Market Updates - StockTitan
FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections - Contagionlive.com
Iterum Scores First Approval For Oral Penem Antibiotic - Citeline
Second Oral UTI Treatment Approved, But Still No Vaccine - Precision Vaccinations
Biotech Alert: Searches spiking for these stocks today - TipRanks
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Benzinga
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment - Pharmaceutical Technology
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - BioSpace
NaoTrac to Redefine Surgical Navigation Robotics at MEDICA 2024 - Lelezard
Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs - MSN
Major Improvements In Iterum Therapeutics Plc (ITRM) Stock Need To Be Considered - Stocks Register
FDA approves new oral antibiotic ORLYNVAH for uUTIs By Investing.com - Investing.com Nigeria
Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal
Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com
Wall Street-Heavily Traded - WDRB
Iterum Therapeutics Shares Soar on FDA's Orlynvah Approval - Marketscreener.com
FDA approves new oral antibiotic ORLYNVAH for uUTIs - Investing.com India
Iterum Therapeutics Gains FDA Approval for ORLYNVAH - TipRanks
US FDA approves Iterum's treatment for urinary infection - Reuters.com
Iterum Therapeutics announces FDA approval of Orlynvah - TipRanks
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Manila Times
Week Ahead (Jul.26-30): INFI To Provide Update On Eganelisib Trials, Writing's On The Wall For ITRM? - RTTNews
Renaissance Technologies LLC Trims Stock Holdings in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics to Present Data at IDWeek 2024 - StockTitan
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Iterum Therapeutics shareholders approve share issuance authority - Investing.com
Iterum Therapeutics shareholders approve share issuance authority By Investing.com - Investing.com Canada
Iterum Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Iterum Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK
Biotech Stocks Facing FDA Decision In October 2024 - RTTNews
IDWeek 2022 PresentationsIVVD, SPRO, INVA, CDTX, ANTX, GSK - RTTNews
Nothing is Better Than Iterum Therapeutics Plc (ITRM) stock at the moment - SETE News
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down - Yahoo Finance
Iterum Therapeutics’ (ITRM) Buy Rating Reaffirmed at HC Wainwright - Defense World
Iterum's oral antibiotic discussed at FDA advisory meeting - Investing.com India
Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug - MSN
A closer look at ITRM’s price-to-free cash flow ratio - US Post News
Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug (NASDAQ:ITRM) - Seeking Alpha
Iterum's oral antibiotic discussed at FDA advisory meeting By Investing.com - Investing.com Canada
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment - EIN News
Iterum Therapeutics Plc (ITRM)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI - Urology Times
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference - StockTitan
Iterum Therapeutics Plc (ITRM)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Finanzdaten der Iterum Therapeutics Plc-Aktie (ITRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):